Email updates

Keep up to date with the latest news and content from Journal for ImmunoTherapy of Cancer and BioMed Central.

Journal App

google play app store
Open Access Highly Accessed Editorial

Introducing the society for immunotherapy of cancer’s new journal: journal for immunoTherapy of cancer

Pedro J Romero1*, Tara Withington2 and Francesco Marincola3

Author Affiliations

1 Ludwig Center for Cancer Research, Lausanne, Switzerland

2 Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, USA

3 Sidra Medical and Research Center, Doha, Qatar

For all author emails, please log on.

Journal for ImmunoTherapy of Cancer 2013, 1:1  doi:10.1186/2051-1426-1-1

Published: 29 May 2013

First paragraph (this article has no abstract)

The field of cancer immunology and immunotherapy is experiencing a tremendous increase in excitement and momentum, catalyzed by the latest approvals of immunotherapy-based treatments in multiple cancer types. Contributing to the excitement, more cancer vaccine candidates, immunomodulatory monoclonal antibodies and cellular therapies are showing great promise and major pharma companies are driving their development into future novel cancer treatments.